We will discuss how high-resolution MS-based approaches, namely Multiple Attribute Method (MAM), together with mass photometry, capillary electrophoresis, and biophysical tools, provide powerful capabilities for the characterization of mAbs and other complex format biotherapeutics. Building on these tools, we expanded our analytical portfolio to support rAAVs characterization, enabling deeper assessment of viral protein ratios, key PTMs (e.g., glycosylation, oxidation, deamidation), and HCPs in both purified and in-process samples.

Monoclonal antibody productivity in CHO cells depends on both sequence design and balanced chain expression. High-throughput screening combined with design-of-experiments enables rapid identification of optimal construct features such as codon usage, signal peptides, kappa/lambda choice, and LC:HC promoter ratios. These strategies accelerate selection of high-yielding candidates, improving titre, cell viability, and predictability before stable cell line development.

Macromolecular complexes are crucial for cellular processes, but studying their structure and function requires producing them in high quality and quantity. This presentation outlines our strategies for recombinant expression, including a multigene expression toolbox designed to optimise the reconstitution of medium- to large-scale multi-protein complexes. Additionally, we will discuss purification and characterisation of these complexes from endogenous sources using CRISPR/Cas9-edited cell lines.

The Baculovirus-based BacMam system has recently regained attention through major therapeutic advancements. The production of complex bio-nanoparticles demands large transgenes and tunable expression, reviving this powerful platform. This presentation will highlight transient applications, recent progress, and introduce our newly developed REM-BAC system for rapid, efficient, and manifold baculovirus-mediated generation of stable mammalian cell lines via viral-footprint-free and site-specific genome integration.

We present a miniaturised expression platform that boosts screening throughput without compromising yield. By reducing culture volumes from 200 mL to 4.2 mL, we increased capacity from tens to hundreds of clones per batch while maintaining g/L production. The workflow integrates expression, purification (including tag removal), and conjugation into an automated, high-throughput process, enabling earlier developability assessment and scalable data generation to support advanced screening and predictive modelling.